In this study, GPAT4 was significantly superior to SLC7A11 as a stand-alone predictor of platinum-resistant ovarian cancer drug resistance (SLC7A11 IHC score AUC 0.908, SLC7A11 expression grouping AUC 0.874, Table S4). This evidence concerns the gene GPAT4 and ovarian carcinoma.